{"id":510057,"date":"2021-07-07T03:03:14","date_gmt":"2021-07-07T07:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/"},"modified":"2021-07-07T03:03:14","modified_gmt":"2021-07-07T07:03:14","slug":"biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/","title":{"rendered":"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor &#8211; peptide-HLA interactions"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">BASEL, Switzerland<\/span> and T\u00dcBINGEN, <span class=\"xn-location\">Germany<\/span>, <span class=\"xn-chron\">July 7, 2021<\/span> \/PRNewswire\/ &#8212; BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) &#8220;Immatics&#8221; in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1558072\/BioCopy_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1558072\/BioCopy_Logo.jpg\" title=\"BioCopy\" alt=\"BioCopy\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Cancer represents one of the most frequent causes of death and thus one of the greatest challenges of modern medicine. Therefore, it is not only necessary but crucial to develop advanced therapies. For this reason, BioCopy has developed an innovative technology that enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes. With this technology BioCopy is contributing a safety screening for novel TCR-based cancer cell therapies.<\/p>\n<p>The extension of BioCopy&#8217;s highly innovative screening platform to provide insight into T cell responses in addition to B-cell responses is a valuable milestone for BioCopy. During the last months, BioCopy has been working to develop this globally unique screening, and a patent application has already been filed on the technology. The goal of this collaboration is to enable the characterization of more than 5,000 different TCR-peptide-HLA interactions simultaneously. This ultra-high-throughput approach could significantly accelerate the development of T cell based cancer therapies by facilitating large pre-clinical safety screenings.<\/p>\n<p>Rainer B\u00f6hm, Member of the Board of Directors of BioCopy comments: &#8220;With its newly patented technology for T cell therapies, BioCopy completes its innovative molecular-interaction screening platform and is one of only a few companies in the world to support targeted therapy development via both pathways of the immune response (B- and T cell response). With its innovative technology platform, BioCopy addresses two booming billion-dollar markets &#8211; infectious diseases and oncology.&#8221;<\/p>\n<p>Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. The BioCopy technology will be implemented as part of Immatics&#8217; XCEPTOR\u00ae platform, which delivers highly specific TCRs for the development of Adoptive Cell Therapies and TCR Bispecifics.<\/p>\n<p>&#8220;Making sure that our TCRs do not cross-react with other tissues than the targeted cancer is very important in the development of our TCR-based immunotherapies&#8221;, says <span class=\"xn-person\">Dominik Maurer<\/span>, Vice President and Global Head of Immunology at Immatics. &#8220;BioCopy&#8217;s screening platform and expertise has produced promising early results. We are looking forward to combining their screening platform with our XCEPTOR\u00ae platform to further advance our pre-clinical product candidates and deliver the power of T cells to cancer patients.&#8221;<\/p>\n<p>About BioCopy:<\/p>\n<p>BioCopy AG is a young biotech startup with headquarters in <span class=\"xn-location\">Basel<\/span> (Switzerland) and a research facility in Emmendingen, <span class=\"xn-location\">Germany<\/span>. BioCopy&#8217;s patented technology portfolio enables a unique label-free measurement of molecular interactions, applied for diagnostics, vaccines, lead and hit screening and was now expanded also to HLA and TCR screening.<\/p>\n<p>BioCopy&#8217;s award winning team of more than 20 experts in the field of biology, physics, engineering, microsystems technology and economics is complemented by renowned board members. Especially <span class=\"xn-person\">Rainer Boehm<\/span> (ex-interim CEO and Chief Commercial and Medical Affairs Officer <span class=\"xn-person\">Novartis Pharma<\/span>), Prof. Dr. Alexander von Gabain (co-founder of Intercell AG, now Valneva SE), and <span class=\"xn-person\">Pascal Brenneisen<\/span> (ex-CEO <span class=\"xn-person\">Novartis Switzerland<\/span>).<\/p>\n<p>Contact International:<br \/><span class=\"xn-person\">Manfred Claassens<\/span>, Presse BioCopy; +49 162 264 44 61; <a href=\"mailto:presse@biocopy.de\" target=\"_blank\" rel=\"nofollow noopener\">presse@biocopy.de<\/a> \u00a0<\/p>\n<p>Contact Switzerland: <br \/><span class=\"xn-person\">Barbara Ryter<\/span>, Presse BioCopy; +41 43 501 33 06; <a href=\"mailto:presse@biocopy.ch\" target=\"_blank\" rel=\"nofollow noopener\">presse@biocopy.ch<\/a><\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN33529&amp;sd=2021-07-07\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor--peptide-hla-interactions-301326020.html\">https:\/\/www.prnewswire.com\/news-releases\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor&#8211;peptide-hla-interactions-301326020.html<\/a><\/p>\n<p>SOURCE  BioCopy<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN33529&amp;Transmission_Id=202107070300PR_NEWS_USPR_____LN33529&amp;DateId=20210707\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire BASEL, Switzerland and T\u00dcBINGEN, Germany, July 7, 2021 \/PRNewswire\/ &#8212; BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) &#8220;Immatics&#8221; in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things. Cancer represents one of the most frequent causes of death and thus one of the greatest challenges of modern medicine. Therefore, it is not only necessary but crucial to develop advanced therapies. For this reason, BioCopy has developed an innovative technology that enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor &#8211; peptide-HLA interactions&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510057","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BASEL, Switzerland and T\u00dcBINGEN, Germany, July 7, 2021 \/PRNewswire\/ &#8212; BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) &#8220;Immatics&#8221; in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things. Cancer represents one of the most frequent causes of death and thus one of the greatest challenges of modern medicine. Therefore, it is not only necessary but crucial to develop advanced therapies. For this reason, BioCopy has developed an innovative technology that enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes. &hellip; Continue reading &quot;BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor &#8211; peptide-HLA interactions&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T07:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1558072\/BioCopy_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor &#8211; peptide-HLA interactions\",\"datePublished\":\"2021-07-07T07:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/\"},\"wordCount\":594,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1558072\\\/BioCopy_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/\",\"name\":\"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1558072\\\/BioCopy_Logo.jpg\",\"datePublished\":\"2021-07-07T07:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1558072\\\/BioCopy_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1558072\\\/BioCopy_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor &#8211; peptide-HLA interactions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/","og_locale":"en_US","og_type":"article","og_title":"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions - Market Newsdesk","og_description":"PR Newswire BASEL, Switzerland and T\u00dcBINGEN, Germany, July 7, 2021 \/PRNewswire\/ &#8212; BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) &#8220;Immatics&#8221; in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things. Cancer represents one of the most frequent causes of death and thus one of the greatest challenges of modern medicine. Therefore, it is not only necessary but crucial to develop advanced therapies. For this reason, BioCopy has developed an innovative technology that enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes. &hellip; Continue reading \"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor &#8211; peptide-HLA interactions\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T07:03:14+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1558072\/BioCopy_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor &#8211; peptide-HLA interactions","datePublished":"2021-07-07T07:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/"},"wordCount":594,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1558072\/BioCopy_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/","name":"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1558072\/BioCopy_Logo.jpg","datePublished":"2021-07-07T07:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1558072\/BioCopy_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1558072\/BioCopy_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-hla-interactions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor &#8211; peptide-HLA interactions"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510057"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510057\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}